A detailed history of Ubs Group Ag transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Ubs Group Ag holds 748,733 shares of OCUL stock, worth $6.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
748,733
Previous 483,506 54.85%
Holding current value
$6.5 Million
Previous $4.4 Million 16.41%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.2 - $8.69 $1.11 Million - $2.3 Million
265,227 Added 54.85%
748,733 $5.12 Million
Q1 2024

May 13, 2024

BUY
$3.85 - $10.93 $1.51 Million - $4.29 Million
392,673 Added 432.3%
483,506 $4.4 Million
Q4 2023

Feb 09, 2024

BUY
$2.08 - $4.52 $77,498 - $168,410
37,259 Added 69.55%
90,833 $405,000
Q3 2023

Nov 09, 2023

SELL
$3.14 - $5.04 $239,823 - $384,940
-76,377 Reduced 58.77%
53,574 $168,000
Q2 2023

Aug 11, 2023

BUY
$4.6 - $7.64 $591,900 - $983,069
128,674 Added 10076.27%
129,951 $670,000
Q4 2022

Feb 08, 2023

BUY
$2.61 - $4.41 $722 - $1,221
277 Added 27.7%
1,277 $3,000
Q3 2022

Nov 10, 2022

SELL
$4.09 - $6.5 $1.4 Million - $2.22 Million
-341,228 Reduced 99.71%
1,000 $4,000
Q2 2022

Aug 10, 2022

BUY
$3.01 - $5.22 $925,105 - $1.6 Million
307,344 Added 881.05%
342,228 $1.38 Million
Q1 2022

May 16, 2022

SELL
$4.83 - $7.35 $289,828 - $441,044
-60,006 Reduced 63.24%
34,884 $173,000
Q4 2021

Feb 14, 2022

SELL
$6.16 - $12.07 $1.43 Million - $2.8 Million
-231,738 Reduced 70.95%
94,890 $661,000
Q3 2021

Nov 15, 2021

SELL
$9.7 - $14.34 $2.5 Million - $3.7 Million
-258,165 Reduced 44.15%
326,628 $3.27 Million
Q2 2021

Aug 13, 2021

BUY
$13.43 - $19.16 $455,666 - $650,079
33,929 Added 6.16%
584,793 $8.29 Million
Q1 2021

May 12, 2021

SELL
$15.82 - $22.11 $1.1 Million - $1.53 Million
-69,232 Reduced 11.16%
550,864 $9.04 Million
Q4 2020

Feb 11, 2021

BUY
$7.91 - $22.95 $3.82 Million - $11.1 Million
483,347 Added 353.46%
620,096 $12.8 Million
Q3 2020

Nov 12, 2020

SELL
$7.36 - $9.87 $204,953 - $274,849
-27,847 Reduced 16.92%
136,749 $1.04 Million
Q2 2020

Jul 31, 2020

BUY
$4.67 - $8.95 $615,067 - $1.18 Million
131,706 Added 400.44%
164,596 $1.37 Million
Q1 2020

May 01, 2020

SELL
$3.95 - $7.4 $78,229 - $146,557
-19,805 Reduced 37.58%
32,890 $163,000
Q4 2019

Feb 14, 2020

BUY
$2.57 - $4.73 $68,906 - $126,820
26,812 Added 103.59%
52,695 $208,000
Q3 2019

Nov 14, 2019

BUY
$3.04 - $5.32 $77,164 - $135,037
25,383 Added 5076.6%
25,883 $79,000
Q1 2019

May 14, 2019

SELL
$3.51 - $4.77 $4,994 - $6,787
-1,423 Reduced 74.0%
500 $2,000
Q4 2018

Feb 14, 2019

SELL
$3.87 - $7.11 $52,682 - $96,788
-13,613 Reduced 87.62%
1,923 $8,000
Q3 2018

Nov 14, 2018

SELL
$5.42 - $6.99 $85,278 - $109,980
-15,734 Reduced 50.32%
15,536 $107,000
Q2 2018

Aug 14, 2018

BUY
$5.99 - $8.17 $142,382 - $194,200
23,770 Added 316.93%
31,270 $211,000
Q1 2018

May 15, 2018

BUY
$4.66 - $7.08 $7,260 - $11,030
1,558 Added 26.22%
7,500 $49,000
Q4 2017

Feb 14, 2018

SELL
$3.73 - $6.37 $8,366 - $14,287
-2,243 Reduced 27.4%
5,942 $26,000
Q3 2017

Nov 14, 2017

BUY
$5.28 - $6.88 $16,024 - $20,880
3,035 Added 58.93%
8,185 $51,000
Q2 2017

Aug 14, 2017

SELL
N/A
-2,406 Reduced 31.84%
5,150 $48,000
Q1 2017

Nov 14, 2017

BUY
N/A
7,556
7,556 $70,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $668M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.